Product Pipeline Descriptions

The information below provides some additional information about the products in CSL's product pipeline. This is a brief overview of the product. Information is organized according to its place in the pipeline.


Market Development

New Indications
Research and pre-clinical studies to seek additional medical use for Fibrinogen concentrate.
New Indications
Research and pre-clinical studies to seek additional medical use for Prothrombin complex concentrate.


New Product Development

Novel Plasma
Identification of novel therapeutic uses for plasma proteins.
Recombinant Coagulation FactorsResearch activities to develop novel strategies for recombinant coagulation factors.
CSL650 rvWF-FPRecombinant von Willebrand factor with extended half-life.
Partnered Vaccine Programs*ISCOMATRIX® Adjuvant Technology - support for strategic partners.
Vaccine to prevent and treat the severe gum disease Periodontitis, caused by the bacterium Porphyromonas gingivalis.
Discovery ProjectsResearch projects aiming to develop recombinant therapeutic proteins, particularly monoclonal antibodies.
CSL324 G-CSFRRecombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases.
CSL346 VEGFBA humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism.
FXIIa Antagonist
Preclinical development program for Anti-FXIIa monoclonal antibody in HAE; potential additional applications include Thrombosis.
Haptoglobin (Hp) / Hemopexin (Hx)Research program on plasma derived Hp and Hpx for potential treatment of Sickle Cell Disease.

Clinical Development

Market Development

Hizentra™ CIDPGlobal study assessing the use of Hizentra™, 20% subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Aortic EU 
Clinical studies testing the use of Fibrinogen concentrate as a quickly administered, fast acting, low volume medicine to microvascular bleeding to reduce the need for donated (allogenic) blood products.
C1-INH SubcutaneousA volume-reduced, lyophilized, pasteurized (nanofiltered) C1 esterase inhibitor concentrate derived from human plasma suitable for the subcutaneous route of administration by self application.


New Product Development

CSL689 rVIIa-FPRecombinant coagulation factor VIIa with extended half-life.Phase I study in healthy volunteers completed. Phase II study to treat patients with inhibitors to commence in 2015.
CSL627 rFVIIIA unique single chain recombinant factor VIII (rFVIII) for treatment of Hemophilia A, pivotal Phase III paediatric study complete.
Partnered Vaccine ProgramsISCOMATRIX® Adjuvant Technology - support for strategic partners.
CSL362 IL-3R
Recombinant Monoclonal Antibody against the IL-3 Receptor for the potential treatment of acute myeloid leukemia. Licensed to Janssen Biotech Inc. Phase I study in AML in progress.
Recombinant monoclonal antibody inhibiting GM-CSF activity by targeting the GM-CSF receptor for use in rheumatoid arthritis. Licensed to Astra Zeneca. Multiple Phase IIb studies in progress.
reconstituted HDL
Reconstituted high density lipoprotein (rHDL) for secondary treatment in acute coronary syndrome; rHDL is made from apoA1 lipoprotein isolated from human plasma then reconstituted with lipid. Phase IIb study in progress.


Registration/Post Launch

Life Cycle Management

 Specialty ProductsExpanding use of specialty products through new geographic markets, medical indications and/or alternate modes of administration.
HaemophiliaRecombinant coagulation factor medicine to treat haemophilia and other coagulation disorders.
ImmunoglobulinsSupporting CSL’s portfolio of intravenous and subcutaneous immunoglobulin therapies.
Influenza VaccinesSupporting seasonal influenza vaccine.


Market Development

Privigen™ CIDPRegulatory approval received in April 2013 in Europe for the use of Privigen™ in CIDP (Chronic Inflammatory Demyelinating Polyneuropathy).
Flexible Dosing
FDA approval to individualize therapy for flexible dosing treatment at regular intervals from daily to once every two weeks in Feb 2015.
Hizentra® JapanThe first 20% high concentration low volume SCIG for convenient self administration. Approval in Japan for PID and SID in Sept 2013.
Kcentra™ US 
Bleeding / Surgery
Kcentra™ (plasma derived concentrate of coagulation factors II, VII, IX and X) approved by the US FDA for use in patients with bleeding associated with vitamin K antagonists and use during urgent surgery/invasisve procedures.
Respreeza® EUAlpha1 - Proteinase Inhibitor in subjects with emphysema due to A1PI deficiency. 

New Product Development

CSL654 rIX-FP Recombinant coagulation factor IX with extended half-life for treatment of Hemophilia B, submitted to FDA December 2014 and EMA March 2015.

© 2017 CSL Limited